select a format

Single User License
USD 250 INR 16018
Site License
USD 500 INR 32035
Corporate User License
USD 750 INR 48053

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Onyx Pharmaceuticals, Inc.-Pharmaceuticals and Healthcare-Deals and Alliances Profile

Onyx Pharmaceuticals, Inc.-Pharmaceuticals and Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH40135D
  • |
  • Pages: 27
  • |
  • May 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company, which develops and commercializes innovative medicines that target the molecular mechanisms causing cancer. It has two oncology franchises one in kinase inhibition and other in proteasome inhibition. The company marketed product portfolio includes Nexavar (sorafenib) and Kyprolis (carfilzomib). Nexavar is approved for the treatment of advanced kidney cancer, unresectable liver cancer and locally recurrent or metastatic, progressive, differentiated thyroid cancer. The company markets and commercializes Nexavar under a collaboration agreement with Bayer. Kyprolis is approved for the treatment of patients with multiple myeloma who have received at least two prior therapies. The company also has a pipeline of drug candidates including carfilzomib; oprozomib,and palbociclib. Onyx is a subsidiary of Amgen Inc. and is headquartered in South San Francisco, California, the US.

Onyx Pharmaceuticals, Inc.-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons To Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 10

Multiple Myeloma Research Enters Into Co-Development Agreement With Onyx Pharma 12

S*Bio Amends Collaboration With Onyx Pharma 13

S*BIO Expands Co-Development Agreement With Onyx Pharma 14

Licensing Agreements 16

Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 16

Onyx Pharma Enters Into Licensing Agreement With Ono Pharma For Carfilzomib And ONX 0912 17

Equity Offering 19

Onyx Pharma Completes Public Offering Of Common Stock For USD 358.6 Million 19

Acquisition 21

Amgen Completes Acquisition of Onyx Pharma For Up To USD 10.4 Billion in Tender Offer 21

Onyx Pharmaceuticals, Inc.-Key Competitors 24

Key Employees 25

Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Appendix 27

Methodology 27

About GlobalData 27

Contact Us 27

Disclaimer 27

List of Figures

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8

List of Tables

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts 1

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7

Onyx Pharmaceuticals, Inc., Deals By Therapy Area, 2010 to YTD 2016 8

Onyx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 10

Multiple Myeloma Research Enters Into Co-Development Agreement With Onyx Pharma 12

S*Bio Amends Collaboration With Onyx Pharma 13

S*BIO Expands Co-Development Agreement With Onyx Pharma 14

Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 16

Onyx Pharma Enters Into Licensing Agreement With Ono Pharma For Carfilzomib And ONX 0912 17

Onyx Pharma Completes Public Offering Of Common Stock For USD 358.6 Million 19

Amgen Completes Acquisition of Onyx Pharma For Up To USD 10.4 Billion in Tender Offer 21

Onyx Pharmaceuticals, Inc., Key Competitors 24

Onyx Pharmaceuticals, Inc., Key Employees 25

Onyx Pharmaceuticals, Inc., Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Onyx Pharmaceuticals, Inc., Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com